---
layout: post
title: "Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry; Availability"
date: 2026-02-05 18:58:06 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-28310
original_published: 2023-12-26 00:00:00 +0000
significance: 8.00
---

# Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** December 26, 2023 00:00 UTC
**Document Number:** 2023-28310

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Rare Diseases: Considerations for the Development of Drugs and Biological Products." This guidance is intended to assist sponsors of drugs and biological products for treatment of rare diseases in conducting efficient and successful drug development programs through a discussion of selected issues commonly encountered in rare disease drug development. This guidance finalizes the draft guidance entitled "Rare Diseases: Common Issues in Drug Development" issued on February 1, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/26/2023-28310/rare-diseases-considerations-for-the-development-of-drugs-and-biological-products-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-28310

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
